Author’s response to reviews

Title: NTP42, a novel antagonist of the thromboxane receptor, attenuates experimentally induced pulmonary arterial hypertension

Authors:

Eamon Mulvaney (eamon.mulvaney@atxatherapeutics.com)
Helen Reid (helen.reid@atxatherapeutics.com)
Lucia Bialesova (lucia.bialesova@atxatherapeutics.com)
Annie Bouchard (abouchard@ipstherapeutique.com)
Dany Salvail (dsalvail@ipstherapeutique.com)
B. Therese Kinsella (Therese.Kinsella@ucd.ie)

Version: 3 Date: 10 Mar 2020

Author’s response to reviews:

ATXA Therapeutics Limited
UCD Conway Institute for Biomolecular and Biomedical Research,
University College Dublin,
Belfield, Dublin 4, Ireland.
Tel: 353-1-7166727
Fax: 353-1-7166456
Email: therese.kinsella@ucd.ie

March 10th, 2020

Attn: Maire Clayton, Assistant Editor, BMC Pulmonary Medicine
Dear Editor,

Further to your email of March 9th, 2020 in which you enclosed the review of our submission - PULM-D-19-00758R2 - we are pleased to note that it is potentially acceptable for publication in BMC Pulmonary Medicine. We now wish to submit a finalized version of the manuscript where we have addressed each of your outstanding editorial comments, as per the responses below.

As per the instructions in your email, we have uploaded our manuscript as a single, final, clean version that does not contain any tracked changes, comments, highlights, strikethroughs or text in different colours. All relevant tables/figures/additional files are also clean versions and all figures and additional files have been uploaded as separate files.

In making this resubmission on behalf of all authors, I trust that the finalized version of the manuscript and this point-by-point response has adequately addressed your editorial comments. However, should you need any additional information from me, I would be happy to assist in whatever way possible.

Yours sincerely and with kind regards,

____________________________
B. Therese Kinsella., Ph.D.
Corresponding Author
Response to Editor:

1. We notice significant text overlap between your manuscript and previously published materials. Please reformulate the large sections of overlapping text present in your Limitations section. Please ensure that, where relevant, these sources are also referenced as appropriate: Pulmonary hypertension: diagnostic approach and optimal management (https://doi.org/10.1503/cmaj.151075).

Author Response: We have now reformulated the text within the Limitations section of our manuscript (Lines 512-515) that may have overlapped with previously published materials. We have also referenced the source outlined above and a number of additional sources to support the reformulated statements.

2. In the methods, please clearly state the method used to euthanize the animals used in the study (if applicable). Please include details of any chemical and/or physical method(s) used, as well as details of the equipment, specific chemical agents and their doses or concentrations.

Author Response: The methods used to euthanize the animals used in the study are detailed in the Methods section:

Lines 142-144 - “All procedures were performed under isoflurane-induced, inhalational anaesthesia to minimize suffering. At the end of the study, following haemodynamic evaluations, animals under anaesthesia were euthanised by exsanguination.”

Lines 147-148 - “At the end of the treatment period, on the afternoon of Day 28 of treatment, animals were anesthetised with a mixture of 2–2.5% isoflurane (Abbott Laboratories, Montreal, Canada) in 95% O2/5% CO2, …”

Line 168 – “Following haemodynamic evaluations, the animal was euthanised by exsanguination, …”

3. Please remove the duplicate manuscript.

Author Response: The duplicate “MARKED” manuscript has been removed.
4. In the Funding section, please also describe the role of the funding body in the design of the study and collection, analysis, and interpretation of data and in writing the manuscript.

Author Response: The funding bodies listed in the Funding section did not play a role in the study design, data collection, data analysis, data interpretation or in writing the manuscript. We have now added a statement to this regard within the Funding section.

5. Please remove the author response and the ARRIVE checklist from the supplementary material.

Author Response: The author response and the ARRIVE checklist has been removed from the supplementary materials.

6. At this stage, please upload your manuscript as a single, final, clean version that does not contain any tracked changes, comments, highlights, strikethroughs or text in different colours. All relevant tables/figures/additional files should also be clean versions. Figures (and additional files) should remain uploaded as separate files.

Author Response: We have uploaded our manuscript as a single, final, clean version that does not contain any tracked changes, comments, highlights, strikethroughs or text in different colours. All relevant tables/figures/additional files are also clean versions and all figures and additional files have been uploaded as separate files.

Response to Reviewer:

Fabrice Antigny (Reviewer 2): All my concerns have been addressed.

Author Response: We thank the reviewer for his previous comments and acknowledge that all his concerns have been addressed in the revised manuscript.